Novartis Stock Gets Reduced EPS Estimate from Zacks Research

Key Points

• Zacks Research cut its FY2028 EPS estimate for Novartis to $10.62 from $10.69; the current-year consensus estimate is $9.08 per share.
• Novartis beat quarterly expectations, reporting EPS of $2.46 versus a $2.25 consensus and revenue of $15.03 billion versus $14.53 billion. Revenue increased 4.4% year over year.
• Analysts’ consensus rating is Hold, with an average price target of $152.25; six analysts rate the stock Buy, nine Hold and three Sell.

Novartis AG (NYSE:NVS - Free Report) - Research analysts at Zacks Research reduced their FY2028 earnings estimates for shares of Novartis in a research note issued to investors on Tuesday, November 10th. Zacks Research analyst Team now expects that the company will earn $10.62 per share for the year, down from their previous forecast of $10.69. The consensus estimate for Novartis' current full-year earnings is $9.08 per share.

Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings results on Tuesday, October 27th. The company reported $2.46 earnings per share for the quarter, topping analysts' consensus estimates of $2.25 by $0.21. Novartis had a net margin of 18.11% and a return on equity of 41.04%. The firm had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.53 billion. During the same quarter in the prior year, the business earned $2.25 EPS. Novartis's quarterly revenue was up 4.4% compared to the same quarter last year.

NVS has been the subject of several other research reports. UBS Group reiterated a "neutral" rating on shares of Novartis in a research note on Wednesday, October 28th. Sanford C. Bernstein restated a "neutral" rating on shares of Novartis in a research report on Wednesday, July 22nd. Morgan Stanley reaffirmed an "overweight" rating and set a $163.00 price objective on shares of Novartis in a research note on Wednesday, October 28th. Citigroup reaffirmed a "buy" rating on shares of Novartis in a research note on Wednesday, July 22nd. Finally, DZ Bank started coverage on Novartis in a research report on Wednesday, October 28th. They set a "hold" rating for the company. Six research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Novartis presently has a consensus rating of "Hold" and an average price target of $152.25.

Novartis Trading Down 1.7%

NYSE NVS opened at $160.41 on Thursday. The firm's fifty day moving average is $149.23 and its two-hundred day moving average is $152.50. Novartis has a one year low of $123.24 and a one year high of $170.46. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.70 and a current ratio of 0.88. The firm has a market cap of $306.08 billion, a PE ratio of 30.61, a P/E/G ratio of 3.00 and a beta of 0.40.

Hedge Funds Weigh In On Novartis

Large investors have recently bought and sold shares of the company. TIAA CREF Individual & Institutional Services LLC raised its stake in shares of Novartis by 1.4% during the 3rd quarter. TIAA CREF Individual & Institutional Services LLC now owns 8,951 shares of the company's stock worth $1,276,000 after buying an additional 121 shares in the last quarter. FCA Corp TX lifted its holdings in shares of Novartis by 0.8% in the 3rd quarter. FCA Corp TX now owns 23,606 shares of the company's stock valued at $3,366,000 after buying an additional 187 shares during the period. Advisors Asset Management Inc. purchased a new stake in shares of Novartis in the third quarter valued at approximately $22,831,000. Private Wealth Asset Management LLC boosted its stake in shares of Novartis by 22.8% in the third quarter. Private Wealth Asset Management LLC now owns 4,821 shares of the company's stock valued at $687,000 after buying an additional 894 shares in the last quarter. Finally, Private Advisor Group LLC boosted its stake in shares of Novartis by 64.2% in the third quarter. Private Advisor Group LLC now owns 47,481 shares of the company's stock valued at $6,769,000 after buying an additional 18,565 shares in the last quarter. Hedge funds and other institutional investors own 13.12% of the company's stock.

Key Stories Impacting Novartis

Investors following NVS have been watching these stories:

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $9.06 from $8.83 and its FY2027 estimate to $9.91 from $9.75. It also lifted estimates for several quarters, signaling improved expectations for earnings in those periods.
• Neutral Sentiment: The estimate revisions were mixed: Zacks lowered forecasts for Q4 2026, Q1 2027, Q1 2028 and Q2 2028, while raising others. The changes are relatively small and do not indicate a broad downgrade to its annual outlook.
• Negative Sentiment: In particular, Zacks reduced its Q1 2028 EPS forecast to $2.45 from $2.54, and its Q2 2028 forecast to $2.70 from $2.72, tempering some of the positive revisions.

Novartis Company Profile

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company's medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.